<iframe src="//www.googletagmanager.com/ns.html?id=GTM-K3L4M3" height="0" width="0" style="display:none;visibility:hidden">

World

Will the Pfizer vaccine live up to the hype?

10 November 2020

1:03 AM

10 November 2020

1:03 AM

So is this the big turning point? Markets certainly seem to think so. No sooner had news broken that the vaccine being developed by Pfizer and German firm BioNTech is 90 per cent effective, the FTSE surged by 5 per cent. Given that the US Food and Drug Administration (FDA) has suggested that any vaccine that proves to be more than 50 per cent effective could be licensed, this suggests the vaccine will go on to be approved around the world.

Already a subscriber? Log in

Easter flash sale:
10 issues for $1

Subscribe this Easter and get the next 10 issues of the magazine, plus website and app access, all for just $1.

  • Weekly delivery of the magazine
  • Unlimited access to spectator.com.au and app
  • Spectator Australia podcasts and newsletters
  • Full access to spectator.co.uk
Or

Unlock 3 articles a month

REGISTER


Comments

Easter flash sale: 10 issues for $1

Join the conversation with other Spectator Australia readers. Subscribe to leave a comment.

Already a subscriber? Log in

Close